BioWorld

April 4, 2016

Complementary approaches yield new target insights

By combining two types of genomic technologies to probe the targets of an experimental antiviral drug, researchers have identified a strategy that may be able to mitigate its toxicity. Read More

Week in review

Week in Washington

Word on the street

Biotech money raised by month in 2016

Public financing of biotechnology companies: Commenced trading in March 2016

Public financing of biotechnology companies: Filed and pending IPOs

2016 top private financings of public companies

Other financings of public biotechnology companies: March 2016

2016 top financings of private companies

Venture capital & other investments in private biotechnology companies: March 2016

Milestone payments from corporate partners: March 2016

Money raised by biotech in 2016 vs. 2015

Money raised by biotech: Jan. 1 - Mar. 31, 2016

The week's biggest gainers and losers

BioWorld stock report for public biotechnology companies

BioWorld Stock Index 2016

Nasdaq Stock Index 2016

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...